Shopping Cart
Remove All
Your shopping cart is currently empty
TAT-EE3
😃Good
Catalog No. TP3908Cas No. 2899218-49-4
TAT-EE3 is a neuroprotective peptide that dissociates the interaction between TRPM2 and NMDARs. It inhibits the TRPM2-induced enhancement of NMDAR surface expression and current amplitude. TAT-EE3 protects neurons from ischemic damage both in vitro and in vivo, and is utilized for research on ischemic stroke.
TAT-EE3
😃Good
Catalog No. TP3908Cas No. 2899218-49-4
TAT-EE3 is a neuroprotective peptide that dissociates the interaction between TRPM2 and NMDARs. It inhibits the TRPM2-induced enhancement of NMDAR surface expression and current amplitude. TAT-EE3 protects neurons from ischemic damage both in vitro and in vivo, and is utilized for research on ischemic stroke.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Resource Download
Product Introduction
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | TAT-EE3 is a neuroprotective peptide that dissociates the interaction between TRPM2 and NMDARs. It inhibits the TRPM2-induced enhancement of NMDAR surface expression and current amplitude. TAT-EE3 protects neurons from ischemic damage both in vitro and in vivo, and is utilized for research on ischemic stroke. |
| In vitro | TAT-EE3 (10 μM, overnight) disrupts the interaction between TRPM2 and GluN2a/GluN2b in HEK293T cells and neurons, inhibiting TRPM2-induced enhancement of NMDA receptor surface expression and current amplitude. TAT-EE3 (10 μM, overnight) reduces OGD-induced intracellular Ca2+ overload, neuronal death, and mitochondrial depolarization in wild-type neurons, but has no effect on global TRPM2 knockout (gM2KO) neurons. TAT-EE3 (10 μM, 30-90 min) eliminates PMA-induced enhancement of NMDA receptor current in wild-type neurons without additional inhibitory effects on gM2KO neurons. |
| In vivo | Fifteen minutes prior to middle cerebral artery occlusion (MCAO), or every 12 hours post-MCAO for 7 days, TAT-EE3 (0.33 mg/kg [100 nmol/kg], administered via intraperitoneal injection) reduced infarct volume and improved neurological deficit scores in wild-type mice. However, this compound did not exhibit enhanced protective effects in neuron-specific TRPM2 knockout (nM2KO) mice. |
| Molecular Weight | 3339.61 |
| Formula | C135H228N48O49S |
| Cas No. | 2899218-49-4 |
| Smiles | [C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CCC(O)=O)C(O)=O)=O)CCC(O)=O)=O)C)=O)CC(C)C)=O)C)=O)CC(C)C)=O)CCSC)=O)CCC(O)=O)=O)CCC(O)=O)=O)CO)=O)CO)=O)CC(O)=O)=O)[C@@H](C)O)=O)CC(O)=O)=O)CCC(O)=O)=O)CCC(O)=O)=O)CCCNC(=N)N)=O)(NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC(CNC([C@H](CC1=CC=C(O)C=C1)N)=O)=O)CCCNC(=N)N)=O)CCCCN)=O)CCCCN)=O)CCCNC(=N)N)=O)CCCNC(=N)N)=O)CCC(N)=O)=O)CCCNC(=N)N)=O)CCCNC(=N)N |
| Sequence | Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Glu-Glu-Asp-Thr-Asp-Ser-Ser-Glu-Glu-Met-Leu-Ala-Leu-Ala-G |
| Sequence Short | YGRKKRRQRRREEDTDSSEEMLALAEE |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy TAT-EE3 | purchase TAT-EE3 | TAT-EE3 cost | order TAT-EE3 | TAT-EE3 chemical structure | TAT-EE3 in vivo | TAT-EE3 in vitro | TAT-EE3 formula | TAT-EE3 molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.